| Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial MJ Pishvaian, EM Blais, JR Brody, E Lyons, P DeArbeloa, A Hendifar, ... The Lancet Oncology 21 (4), 508-518, 2020 | 402 | 2020 |
| Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative MJ Pishvaian, RJ Bender, D Halverson, L Rahib, AE Hendifar, S Mikhail, ... Clinical Cancer Research 24 (20), 5018-5027, 2018 | 209 | 2018 |
| Reconciled rat and human metabolic networks for comparative toxicogenomics and biomarker predictions EM Blais, KD Rawls, BV Dougherty, ZI Li, GL Kolling, P Ye, A Wallqvist, ... Nature communications 8 (1), 14250, 2017 | 162 | 2017 |
| Matrix rigidity regulates cancer cell growth by modulating cellular metabolism and protein synthesis RW Tilghman, EM Blais, CR Cowan, NE Sherman, PR Grigera, ED Jeffery, ... PloS one 7 (5), e37231, 2012 | 88 | 2012 |
| Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix H Jiang, RJ Torphy, K Steiger, H Hongo, AJ Ritchie, M Kriegsmann, ... The Journal of clinical investigation 130 (9), 4704-4709, 2020 | 87 | 2020 |
| Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens DM Walters, JB Stokes, SJ Adair, EB Stelow, CA Borgman, BT Lowrey, ... PloS one 8 (10), e77065, 2013 | 78 | 2013 |
| Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: results from the know your tumor program MJ Pishvaian, EM Blais, JR Brody, L Rahib, E Lyons, P De Arbeloa, ... JCO Precision Oncology 3, 1-10, 2019 | 72 | 2019 |
| A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients MJ Pishvaian, EM Blais, RJ Bender, S Rao, SM Boca, V Chung, ... JAMIA open 2 (4), 505-515, 2019 | 59 | 2019 |
| Electrophysiology-based stratification of pancreatic tumorigenicity by label-free single-cell impedance cytometry JS McGrath, C Honrado, JH Moore, SJ Adair, WB Varhue, A Salahi, ... Analytica chimica acta 1101, 90-98, 2020 | 51 | 2020 |
| A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest TE Newhook, EM Blais, JM Lindberg, SJ Adair, W Xin, JK Lee, JA Papin, ... PloS one 9 (9), e105631, 2014 | 38 | 2014 |
| Testicular expression of Adora3i2 in Adora3 knockout mice reveals a role of mouse A3Ri2 and human A3Ri3 adenosine receptors in sperm LA Burnett, EM Blais, JD Unadkat, B Hille, SL Tilley, DF Babcock Journal of biological chemistry 285 (44), 33662-33670, 2010 | 27 | 2010 |
| A simplified metabolic network reconstruction to promote understanding and development of flux balance analysis tools KD Rawls, BV Dougherty, EM Blais, E Stancliffe, GL Kolling, K Vinnakota, ... Computers in Biology and Medicine 105, 64-71, 2019 | 26 | 2019 |
| Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies A Hendifar, EM Blais, B Wolpin, V Subbiah, E Collisson, I Singh, ... JCO precision oncology 5, 1325-1338, 2021 | 25 | 2021 |
| Multi-omic molecular comparison of primary versus metastatic pancreatic tumours G Brar, EM Blais, R Joseph Bender, JR Brody, D Sohal, S Madhavan, ... British journal of cancer 121 (3), 264-270, 2019 | 24 | 2019 |
| Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program. MJ Pishvaian, EM Blais, JR Brody, D Sohal, AE Hendifar, V Chung, ... Journal of Clinical Oncology 37 (4_suppl), 191-191, 2019 | 22 | 2019 |
| Targeting the NTRK fusion gene in pancreatic acinar cell carcinoma: a case report and review of the literature M Gupta, C Sherrow, ME Krone, EM Blais, MJ Pishvaian, EF Petricoin, ... Journal of the National Comprehensive Cancer Network 19 (1), 10-15, 2021 | 19 | 2021 |
| Genome-scale characterization of toxicity-induced metabolic alterations in primary hepatocytes KD Rawls, EM Blais, BV Dougherty, KC Vinnakota, VR Pannala, ... Toxicological Sciences 172 (2), 279-291, 2019 | 17 | 2019 |
| Linking genome-scale metabolic modeling and genome annotation EM Blais, AK Chavali, JA Papin Systems Metabolic Engineering: Methods and Protocols, 61-83, 2013 | 15 | 2013 |
| Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical/molecular correlations and real-world outcomes across standard therapies. AE Hendifar, EM Blais, C Ng, D Thach, J Gong, D Sohal, V Chung, ... Journal of Clinical Oncology 38 (15_suppl), 4641-4641, 2020 | 12 | 2020 |
| A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience CY Lowder, T Dhir, AB Goetz, HL Thomsett, J Bender, T Tatarian, ... Surgical oncology 33, 118-125, 2020 | 6 | 2020 |
